亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

Diabetes Imaging Agent

技术优势
Improve early diagnosis, help monitor disease progression, provide tools to measure responsiveness to therapy and evaluate the efficiency of islet transplantation and graft survival.
技术应用
Method for screening subjects to determine those subjects more likely to develop diabetes by quantization of insulin producing cells. Diagnosis of diabetes to monitor disease progression or treatment efficacy of candidate drugs.
详细技术说明
D2 receptors (D2R) for dopamine were recently reported on rodent and human islets. University of California researchers propose to use a commercially available ligand with sub-nanomolar affinity and a high degree of specificity for D2R/D3R radiolabeled with fluorine-18 (half-life = 110 minutes) as a positron emission tomography (PET)-scanning agent to quantify changes in β-cell mass associated with diabetes mellitus. The fluorine-18 (18F) radioligand for dopamine D2 receptors (D2R) will be injected into diabetic patients. The radioligand will bind to the D2Rs in islets allowing the radioactive uptake by PET-CT scanning. Loss of beta cells will result in loss of radioligand binding to the pancreas. Since uptake of the radioligand in the liver is low, it may be feasible to detect small changes in the pancreas due to reduced background interference. The use of fluorine-18 as a radiolabel allows the use of the radioligand at facilities that do not have a cyclotron. Furthermore, the ligand is approved for human use making it eminently suitable as a diagnostic tool for T1DM.
*Abstract

The present invention is related generally to a method for screening subjects to determine those subjects more likely to develop diabetes by quantization of insulin producing cells. The present invention is also related to the diagnosis of diabetes to monitor disease progression or treatment efficacy of candidate drugs.

*IP Issue Date
May 30, 2017
*Principal Investigation

Name: Philippe Azam

Department:


Name: George Chandy

Department:


Name: Balu Easwaramoorthy

Department:


Name: Joseph Mantil

Department:


Name: Norah Milne

Department:


Name: Jogeshwar Mukherjee

Department:


Name: Ping Wang

Department:

附加资料
Patent Number: US20080319310A1
Application Number: US2008110135A
Inventor: Mukherjee, Jogeshwar | Chandy, George | Milne, Norah | Wang, Ping H. | Easwaramoorthy, Balu | Mantil, Joseph
Priority Date: 26 Apr 2007
Priority Number: US20080319310A1
Application Date: 25 Apr 2008
Publication Date: 25 Dec 2008
IPC Current: A61B0005055
US Class: 600420
Title: Imaging Agents For Monitoring Changes Of Dopamine Receptors And Methods Of Using Thereof
Usefulness: Imaging Agents For Monitoring Changes Of Dopamine Receptors And Methods Of Using Thereof
Summary: The method is useful for monitoring changes in beta cell mass in a patient, where the patient is at preclinical or clinical stage of diabetes such as Type I or Type II diabetes (all claimed).
Novelty: Non-invasive method for monitoring changes in beta cell mass in subject, involves detecting level of dopamine receptor in pancreas of subject
主要类别
诊断/治疗
细分类别
其他疾病
申请号码
9662059
其他

Tech ID/UC Case

19364/2007-169-0


Related Cases

2007-169-0

国家/地区
美国

欲了解更多信息,请点击 这里
移动设备